Published online September 1, 2004
PEDIATRICS Vol. 114 No. 3 September 2004, pp. 755-761 (doi:10.1542/peds.2003-0592-F)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poehling, K. A.
Right arrow Articles by Griffin, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poehling, K. A.
Right arrow Articles by Griffin, M. R.
Related Collections
Right arrow Infectious Disease & Immunity

Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children

Katherine A. Poehling, MD, MPH*, Bonnie J. Lafleur, PhD, MPH{ddagger}, Peter G. Szilagyi, MD, MPH§, Kathryn M. Edwards, MD*, Ed Mitchel, MS||, Richard Barth, MS§, Benjamin Schwartz, MD and Marie R. Griffin, MD, MPH||,#,**

* Departments of Pediatrics
{ddagger} Biostatistics
|| Preventive Medicine
# Medicine
** Center for Education and Research on Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee
§ Department of Pediatrics and Strong Children's Research Center, University of Rochester School of Medicine and Dentistry, Rochester, New York
New Vaccine Surveillance Network, Centers for Disease Control and Prevention, Atlanta, Georgia

Objective. To determine the population impact of pneumococcal conjugate vaccine (PCV) on pneumococcal-related diseases, including pneumonia and otitis media.

Methods. Using administrative data from Tennessee Medicaid and 3 commercial insurance plans in upstate New York, we measured annual rates of medical visits for pneumococcal-related diseases (pneumococcal and nonspecific pneumonia and invasive disease; otitis media) and pneumococcal-unrelated diseases (other acute respiratory illnesses). Disease rates before (1995–2000 in Tennessee; 1998–2000 in New York) and after (2000–2002) PCV licensure were calculated for children aged <2 years (eligible for PCV) and those 3 to 5 years (not routinely given PCV). Because annual variations should affect both age groups similarly and vaccine-related outcomes should preferentially decline in younger children, ratios (<2:3–5 years) of disease rates before and after PCV licensure were compared. Expected disease rates were calculated for children aged <2 years in each postvaccine year. The difference between observed and expected disease rates was the estimated vaccine effect.

Results. In 2001–2002, there were 67 380 and 9485 child-years of observation for Tennessee and New York children aged <2 years, respectively. We observed fewer visits for pneumonia and invasive disease per 1000 children than expected in both regions: 20 fewer emergency department or outpatient visits in Tennessee and 33 fewer outpatient visits in New York. Otitis media visits declined by 118 and 430 per 1000 children in Tennessee and New York, respectively.

Conclusions. Adding PCV to the childhood immunization schedule was associated with a 10-fold greater reduction in pneumonia and a 100-fold greater reduction in otitis media than the previously reported reduction in culture-confirmed invasive pneumococcal diseases of 1.3 episodes per 1000 children aged <2 years. Although additional studies are needed to confirm the impact of routine immunization with PCV on pneumococcal-related disease, these results suggest that its impact is substantially greater than the effects on invasive disease alone.

Key Words: pneumococcal conjugate vaccine • otitis media • pneumonia • Streptococcus pneumoniae

Abbreviations: PCV, pneumococcal conjugate vaccine • CI, confidence interval • ICD-9, International Classification of Diseases, 9th Revision • ED, emergency department

Accepted Dec 22, 2003.




This article has been cited by other articles:


Home page
 PediatricsHome page
K. A. Poehling, P. G. Szilagyi, C. G. Grijalva, S. W. Martin, B. LaFleur, E. Mitchel, R. D. Barth, J. P. Nuorti, and M. R. Griffin
Reduction of Frequent Otitis Media and Pressure-Equalizing Tube Insertions in Children After Introduction of Pneumococcal Conjugate Vaccine
Pediatrics, April 1, 2007; 119(4): 707 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S L Block
Searching for the Holy Grail of acute otitis media.
Arch. Dis. Child., December 1, 2006; 91(12): 959 - 961.
[Full Text] [PDF]

Home page
 PediatricsHome page
P. G. Szilagyi, M. R. Griffin, L. P. Shone, R. Barth, Y. Zhu, S. Schaffer, S. Ambrose, J. Roy, K. A. Poehling, K. M. Edwards, et al.
The Impact of Conjugate Pneumococcal Vaccination on Routine Childhood Vaccination and Primary Care Use in 2 Counties
Pediatrics, October 1, 2006; 118(4): 1394 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. G. Grijalva, K. A. Poehling, J. P. Nuorti, Y. Zhu, S. W. Martin, K. M. Edwards, and M. R. Griffin
National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States
Pediatrics, September 1, 2006; 118(3): 865 - 873.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
Pneumococcal Vaccine Reduces Childhood Pneumonia and Otitis
Journal Watch Infectious Diseases, September 27, 2004; 2004(927): 6 - 6.
[Full Text]